ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $504.24 ($500.08–$512.36, $4.79M total) across 12 trades on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale of 9,500 shares (weighted average about $504.24) is a discrete datapoint for insider activity, but it does not, by itself, change the company’s fundamentals or forward outlook.
Market read
Traders may monitor insider activity for sentiment, but a 10b5-1 sale typically carries limited predictive power absent other catalysts.
What to watch
The sale is indirect and pre-arranged; without additional context (e.g., changes in other insiders, concurrent buys, or new guidance), the signal-to-noise is low.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, reported by CEO and Chairperson Martine Rothblatt, with a stated 10b5-1 plan.
Ticker impact
United Therapeutics Form 4 shows CEO and Chairperson Martine Rothblatt sold $4.79M of UTHR shares via a 10b5-1 plan on 2026-08-13.
Low near-term impact; any reaction is likely muted and short-lived unless accompanied by other new company-specific news.
This is an SEC Form 4 disclosure of an open-market sale with stated 10b5-1 pre-arrangement, and the article provides no new operational, regulatory, or financial catalyst beyond the transaction details.
Market effects
No direct sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, large insider sales can still coincide with private views on valuation or near-term risk, so traders may treat it as a mild caution signal.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction disclosure.
- insiderMartine A. Rothblatt
CEO and Chairperson reporting an open-market sale under a 10b5-1 plan.
